Status:
COMPLETED
To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
Lead Sponsor:
Enzychem Lifesciences Corporation
Conditions:
COVID-19
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
Prevention of COVID-19 infection to severe pneumonea or ARDS
Eligibility Criteria
Inclusion
- Signed informed consent
- Male or female age 19 years or older
- Pathologically confirmed diagnosis of COVID-19 Infection to Pneumonia
Exclusion
- Pathologically confirmed diagnosis of bacterial pneumonia or viral pneumonia
- Pregnant or nursing at the time of signing informed consent
- Known sensitivity to any study medication
- Unwilling or unable to complete study diary
- Any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the protocol
Key Trial Info
Start Date :
May 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 15 2021
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT04500132
Start Date
May 28 2020
End Date
February 15 2021
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chungbuk National University Hospital
Cheongju-si, South Korea